)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nuvalent
Nuvalent (NUVL) investor relations material
Nuvalent has been acquired by GSK plc
Nuvalent AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary16 Jun, 2026
Opening remarks and agenda
Meeting called to order by the CEO, with all board members and key executives introduced.
Meeting held virtually, following the format from the previous year.
Rules of conduct and participation outlined for attendees.
Corporate governance
Notice of meeting and proxy statement were sent to all stockholders of record as of April 20, 2026.
Quorum established with a majority of Class A common stock represented.
Board and executive committee updates
Election of two Class 2 directors for a three-year term was on the agenda.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nuvalent
- Pivotal data and regulatory filings for ALK and ROS1 programs are expected in 2024.NUVL
TD Cowen 45th Annual Healthcare Conference - Pivotal ROS1 data release imminent, with broad inclusion and focus on rapid, differentiated approvals.NUVLTD Cowen's 6th Annual Oncology Innovation Summit
- Durable responses and strong enrollment position both lead programs for pivotal data in 2025.NUVLEuropean Society for Medical Oncology Congress (ESMO) 2024
- Advancing global launches of innovative NSCLC therapies with strong clinical and financial momentum.NUVLGuggenheim Securities Emerging Outlook: Biotech Summit 2026
- Two major drug launches in 2024, with neladalkib poised to shift ALK treatment standards.NUVLJefferies Global Healthcare Conference 2026
- Two commercial launches and pivotal trial progress position the pipeline for major impact in oncology.NUVL7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- Pivotal data for lead NSCLC therapies support 2026 launches and strong market growth.NUVLCorporate presentation
- Q1 2026 net loss was $109.3M as lead oncology programs reached NDA stage and cash stood at $1.3B.NUVLQ1 2026
- Neladalkib achieves durable efficacy and strong CNS activity in ALK-positive NSCLC.NUVLStudy Update
Nuvalent
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients. The company specializes in the creation of small molecule inhibitors that are designed to target specific kinases with high precision. Its leading product candidates include NVL-520, which targets ROS1-positive non-small cell lung cancer, and NVL-655, aimed at addressing ALK-positive cancers. Both candidates are designed to overcome resistance and minimize adverse events associated with existing treatments. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.